L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab-Reference-Cited by-同舟云学术

L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab

Published:2023-08 Issue:8 Volume:4 Page:101142
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Marrocco Ilaria,Giri Suvendu,Simoni-Nieves Arturo,Gupta Nitin,Rudnitsky Anna,Haga Yuya,Romaniello Donatella,Sekar Arunachalam,Zerbib Mirie,Oren Roni,Lindzen Moshit,Fard Damon,Tsutsumi Yasuo,Lauriola Mattia,Tamagnone Luca,Yarden Yosef^ORCID

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference61 articles.

1. Precision oncology: an overview;Garraway;J. Clin. Oncol.,2013

2. Comprehensive molecular profiling of lung adenocarcinoma;Nature,2014

3. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Med.,2005

4. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib;Kobayashi;N. Engl. J. Med.,2005

5. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer;Oxnard;Clin. Cancer Res.,2011

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC–MS, network Pharmacology, Docking, and molecular dynamics;Saudi Pharmaceutical Journal;2024-09

2. Computational insights into the stereo-selectivity of catechins for the inhibition of the cancer therapeutic target EGFR kinase;Frontiers in Pharmacology;2024-01-11

3. Impact of synthesis methods on the functionality of antibody-conjugated gold nanoparticles for targeted therapy;Nanoscale Advances;2024

4. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators;Cancers;2023-10-16

5. Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges;Genes;2023-10-04